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Background: Current guidelines recommend biannual surveillance for 
hepatocellular carcinoma (HCC) in all patients with cirrhosis, regardless of 
etiology. However, HCC incidence is not well established for many causes of 
cirrhosis.  
Aim: To assess the disease-specific incidence of HCC in a large cohort of 
patients with cirrhosis and to develop a scoring system to predict HCC risk.   
Methods: A derivation cohort of patients with cirrhosis diagnosed by biopsy or 
non-invasive measures was identified through retrospective chart review. The 
disease-specific incidence of HCC was calculated according to etiology of 
cirrhosis. Factors associated with HCC were identified through multivariable Cox 
regression and used to develop a scoring system to predict HCC risk. The 
scoring system evaluated in an external cohort for validation. 
Results: Of 2,079 patients with cirrhosis and ≥6 months follow-up, 226 (10.8%) 
developed HCC. The 10-year cumulative incidence of HCC varied by etiologic 
category from 22% in patients with viral hepatitis, to 16% in those with 
steatohepatitis and 5% in those with autoimmune liver disease (p<0.001). By 
multivariable Cox regression, age, sex, etiology and platelets were associated 
with HCC. Points were assigned in proportion to each hazard ratio to create the 
Toronto HCC Risk Index (THRI). The 10-year cumulative HCC incidence was 3%, 
10% and 32% in the low (<120 points) medium (120-240) and high (>240) risk 
groups respectively, values that remained consistent after internal validation. 
External validation was performed on a cohort of patients with PBC, HBV and 
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HCV cirrhosis (n= 1,144) with similar predictive ability (Harrell’s c-statistic 0.77) in 
the validation and derivation cohorts.   
Conclusion: HCC incidence varies markedly by etiology of cirrhosis. The THRI, 
using readily available clinical and laboratory parameters, has good predictive 
ability for HCC in patients with cirrhosis, and has been validated in an external 
cohort. This risk score may help to guide recommendations regarding HCC 
surveillance among patients with cirrhosis.  
Keywords: Cirrhosis, hepatocellular carcinoma, HCC, Toronto hepatoma risk 
index (THRI), cumulative incidence 
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Introduction 
Ambulatory management of cirrhosis is of increasing importance with rising rates 
of chronic liver disease and the associated complications of end-stage cirrhosis. 
One such complication, hepatocellular carcinoma (HCC), is the fifth most 
common malignancy among men globally, and seventh most common 
malignancy among women, leading to more than 700,000 deaths annually[1-3]. 
In the US, the age-adjusted incidence of HCC rose from 1.6 to 4.5 per 100,000 
people between 1975 and 2005[4]. Currently, one-year survival for HCC is still 
less than 50%, despite improvements in early recognition using surveillance and 
the availability of better therapies[4-6]. 
Current guidelines recommend twice-yearly ultrasounds for HCC surveillance in 
all patients with cirrhosis [6,7]. These recommendations[8] arise from studies 
evaluating HCC doubling time[9,10], cost-effectiveness[11], as well as one 
randomized trial of HCC surveillance in patients with chronic hepatitis B (CHB) 
infection from China[12].  AASLD guidelines state that HCC surveillance is cost-
effective at an annualized incidence of 1.5% or above in patients with cirrhosis[6].  
However, the risk of HCC in cirrhotic patients is known to vary with etiology, age, 
gender and other factors[13-16]. Scoring systems have been developed for HCC-
risk prediction in patients with specific causes of liver disease such as CHB, 
however etiology-independent risk stratification is currently not possible. As a 
result, HCC surveillance is recommended for all patients with cirrhosis, 
regardless of the etiology of liver disease or the presence of other risk factors.  
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Using sequential data from a large cohort of well-characterized patients with 
cirrhosis, we aimed to assess the disease-specific incidence of HCC. Combining 
etiology of liver disease with other risk factors for HCC, we developed and both 
internally and externally validated a scoring system to accurately predict the 5- 
and 10-year risk of HCC among patients with cirrhosis.  
Methods 
Patients 
Complete records were obtained for all patients seen at the Toronto Western 
Hospital Liver Centre between January 1, 2000 and December 31, 2009. The 
study was approved by the Research Ethics Board at the University Health 
Network. 
Diagnosis of cirrhosis and HCC 
To identify a cohort of patients with cirrhosis, patients were evaluated in a step-
wise manner. The AST to platelet ratio index (APRI) [(AST/upper limit of 
normal/platelet count)× 100] and FIB-4 [age × AST/platelet count × √ALT] 
were used to identify patients with probable cirrhosis. To maximize specificity for 
the diagnosis of cirrhosis, only those with an APRI value ≥ 1.0 (Specificity 75%, 
sensitivity 89%) [17] and a FIB-4 value ≥ 3.25 (Specificity 98%, Sensitivity 37%) 
[18] at either the first or last clinic visit were included in the analysis.  To confirm 
the diagnosis of cirrhosis, the charts of all patients identified using non-invasive 
markers, were reviewed to document at least one of: clinical (varices, variceal 
hemorrhage, ascites), pathological (F3 or F4 on biopsy) or radiological 
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(coarse/nodular/lobar redistribution on ultrasound) evidence of cirrhosis.  Patients 
with no confirmatory features were excluded from further analysis. The primary 
etiology of cirrhosis was assigned according to the ‘diagnosis field’ in the 
electronic patient record, as determined by the consultant hepatologist. Patients 
with steatohepatitis were categorized as having alcoholic cirrhosis if alcohol was 
identified as the cause of liver disease by the treating physician in the clinical 
record. Patients with both, chronic viral hepatitis, and a history of alcohol intake 
or non-alcoholic steatohepatitis were categorized as having viral hepatitis for the 
purpose of this analysis. Treatment status for HCV and HBV patients was also 
recorded. The category of ‘other’ included patients with a diagnosis of Wilson 
disease, hereditary hemochromatosis, alpha-1 antitrypsin deficiency and 
cryptogenic cirrhosis.  
The diagnosis of HCC was made in accordance with AASLD guidelines[6] and 
required either a positive ultrasound with confirmation on a second dynamic 
imaging modality (CT or MR) or a diagnostic biopsy. Demographic, clinical and 
laboratory parameters were recorded for all visits including: age, sex, etiology of 
cirrhosis, body mass index (BMI), liver enzyme (AST, ALT, ALP), liver function 
(bilirubin, albumin, INR) and platelet levels. Missing data were imputed using last 
observation carried forward within a window of 3 months. Follow-up time was 
censored at the last clinic visit or diagnosis of HCC. HCCs diagnosed within 6 
months of referral were excluded from further analysis. Patients with primary 
sclerosing cholangitis (PSC) were censored at the time of diagnosis of 
cholangiocarcinoma and these were not included for HCC incidence.    
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Statistical Analysis 
The incidence of HCC was determined for each etiology of cirrhosis using the 
Kaplan-Meir (K-M) method, with curves compared using the log-rank test. 
Continuous variables were compared using Student’s t-test or Wilcoxon Rank 
Sum test. Categorical variables were compared using Fisher’s exact test.  
Cox proportional hazards regression was used to identify factors at the time of 
the diagnosis of cirrhosis that were significantly associated with development of 
HCC. For continuous covariates, threshold values were determined to improve 
clinical utility. Covariates associated by univariate analysis (p<0.15) were 
combined in a backward stepwise multivariable model.  Factors not significant 
but of potential clinical importance (MELD, BMI) and interaction terms were also 
assessed to exclude important confounding. The final model was selected by 
minimizing the Akaike information criterion (AIC). Schoenfeld’s residuals were 
evaluated to ensure validity of the assumptions used in Cox methodology. 
Statistical analysis was carried out using Stata 12 (Texas, USA), and R version 
3.1.2 (R core development team, 2010).   
Internal validation 
To assess the degree of optimism, or over-fitting, in the performance of the final 
predictive model, we estimated the optimism using Harrell’s method[19] and then 
computed an optimism-corrected C-index. To quantify the degree of over-fitting 
of the final model we also estimated the shrinkage factor using the bootstrap[19]. 
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The bootstrap analysis was done using R V3.2.2 (RMS package) with 1000 
iterations performed.  
Derivation of Toronto HCC Risk Index 
To improve clinical utility of the model, a simple scoring system was derived by 
assigning points for each covariate in proportion to the hazard ratios in the final 
multivariable model, as previously described[20]. The THRI score was divided 
into three equally spaced categories to obtain low (<120), medium (120-240) and 
high (>240) risk thresholds. Using the 5- and 10-year cumulative HCC incidence 
at each point score, a nomogram was developed to predict HCC risk by total 
point score.  The performance of the original multivariable model and of the THRI 
strata were then evaluated using an optimism-corrected Harrell's c-
statistic[21,22]. A c-statistic of 0.7-0.8 is considered good, while >0.8 is 
considered excellent [18]. 
External Validation 
The THRI score was validated in an external cohort of cirrhotic patients from 
Rotterdam, Netherlands. Validation was performed in the external cohort with the 
variables in categorical format with the pre-specified cut-offs determined in the 
discovery cohort[23]. Data were obtained from four published cohorts[24-27]. 
Cirrhosis was defined by the presence of clinical or radiologic features, or liver 
biopsy. The THRI and the predicted HCC incidence (calculated using the formula 
S1=1-S0(t)exp(β*THRI)) were calculated for each patient. S0(t) is the baseline HCC 
free-survival in the derivation cohort and β is the estimated effect of THRI in the 
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derivation cohort.  Harrell’s c-statistic was calculated to evaluate the performance 
of the model. Discrimination of the THRI risk score were assessed by plotting the 
observed HCC incidences of the risk groups using the Kaplan-Meier method, 
together with the predicted HCC incidence from the formula above (figure 4).    
 
Results 
Identification of the study cohort 
A total of 12,199 patients (Supplementary Figure 1) were seen at the Liver 
Centre between January 1, 2000 and December 31, 2009. Of these, 3,064 (25%) 
patients had an APRI≥1.0 and FIB-4≥3.25, suggesting probable cirrhosis. The 
charts of all 3,064 patients were reviewed. Of these, 2,416 patients (79%) had 
evidence of varices/ascites (n=1,567), F3/F4 on biopsy (n=1,178) and/or a 
coarse/nodular liver or lobar redistribution on ultrasound (n=2,121). Of those with 
confirmed cirrhosis (n=2,416), 2,079 (98%) patients were followed for ≥ 6 months, 
and formed the study cohort. Using AASLD criteria, 226 patients (10.8%) were 
diagnosed with HCC during follow-up.  
Baseline characteristics  
The baseline characteristics of the study population are shown in Table 1.  The 
most common causes of cirrhosis were chronic hepatitis C (CHC, n=883), 
chronic hepatitis B (CHB, n=396), alcoholic (ALD, n=228) and non-alcoholic fatty 
liver disease (NAFLD, n=111). A large number of patients with autoimmune liver 
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diseases (n=260) were also included: autoimmune hepatitis (AIH) 112, primary 
biliary cirrhosis (PBC) 108 and PSC 40.   
 
Patients who developed HCC were more likely to be male (HCC: 81% vs. no 
HCC: 58%, (p<0.001) and older at baseline (HCC: 57±11 vs. non-HCC: 54±13, 
p<0.001) than patients who did not develop HCC during follow-up. The mean 
duration of follow-up was significantly shorter in the HCC group (HCC: 3.9 ± 3.6 
years vs. No HCC: 6.1 ± 2.6, years; p<0.001), presumably because follow-up 
was censored at HCC diagnosis. Among patients who developed HCC during 
follow-up, a higher proportion had chronic viral hepatitis (79.6%) and fewer had 
an autoimmune liver disease (AIH/PBC/PSC; 3.1%) or ‘other’ etiology (4.9%) as 
the cause of cirrhosis.  As expected, there were differences in demographic (sex, 
age) and clinical features (BMI) between patients with different etiologies of liver 
disease (Table 4).  
 
HCC incidence by etiology  
The cumulative incidence of HCC was calculated for each etiology of cirrhosis. 
Figure 1 shows the 5- and 10-year cumulative incidence for HCC according to 
etiology. HCC occurred most frequently in patients with chronic viral hepatitis 
with a 10-year cumulative incidence of 23.2% among patients with CHB and 
21.1% among those with CHC (p=0.21). Viral clearance is associated with a 
significant reduction in the incidence of HCC in patients with CHC-related 
cirrhosis [27].   Patients with CHC who achieved SVR had a 10-year incidence of 
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HCC of 7%, significantly lower than that seen in patients who remained viremic 
(24.6%). This translated to an incidence rate of 26.2 (CHB), 27.0 (CHC without 
SVR) and 7.0 (CHC with SVR) per 1,000 patient-years respectively.  
The HCC incidence was in the intermediate range in the steatohepatitis cohort 
(ALD and NAFLD). Patients with ALD had 10-year cumulative incidence of HCC 
of 17.7% compared to 12.8% among those with NAFLD (p=0.59). The 
corresponding incidence rates were 18.4 (ALD, 95% CI 11.9-28.5) and 14.4 
(NAFLD, 95% CI 7.2-28.8) per 1,000 patient-years, respectively.  
Patients with ‘other’ liver diseases had a cumulative HCC incidence of 4.5% at 5 
years and 8.0% at 10 years, corresponding to an incidence rate of 10.1 (95% CI 
5.6-18.3) per 1,000 patient-years. 
By contrast, HCC incidence was lower in those with autoimmune liver disease. In 
patients with AIH, no cases of HCC were diagnosed at 5 years of follow-up, and 
the cumulative incidence was 1.7% at 10 years. For patients with PBC the 
cumulative incidence of HCC was 6.1% at 10 years, while in patients with PSC, it 
was 6.9%. The corresponding incidence rates were 1.3 for AIH (95% CI 0.2-9.4), 
5.5 for PBC (95% CI 2.0-14.6) and 7.2 for PSC (95% CI 1.8-28.9) per 1,000 
patient-years of follow-up (log-rank test p=0.09). One patient was diagnosed with 
mixed HCC-Cholangiocarcinoma, but was excluded because the tumor was 
diagnosed within 6 months of the start of follow-up.  
The cumulative incidence was also compared between four broad etiologic 
categories of cirrhosis: viral hepatitis (CHB and CHC), steatohepatitis (ALD and 
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NAFLD), autoimmune (AIH, PBC and PSC) and other liver diseases. Patients 
with viral hepatitis had the highest 10-year cumulative incidence of HCC at 
21.7% compared to 16.3% in those with steatohepatitis, 4.6% in those with 
autoimmune liver disease and 8.0% in those with other liver disease. By the log-
rank test, the cumulative incidence of HCC was significantly higher in patients 
with viral hepatitis or steatohepatitis compared to those with autoimmune liver 
disease (p<0.001). The difference in incidence between viral etiologies and 
steatohepatitis did not reach statistical significance (p=0.09) (Figure 1). 
Cox regression was used to compare the incidence of HCC by etiology of liver 
disease.  Using autoimmune liver disease as a reference, the hazard ratios (HR) 
and 95% confidence intervals (CI) for HCC were 5.8 (95% CI 2.8-12.4) for viral 
hepatitis and 4.1 (95% CI 1.8-9.5) for steatohepatitis. After adjusting for age and 
sex, the HR for HCC was 4.0 (95% CI 1.9-8.6) for all viral hepatitis, 2.7 for 
steatohepatitis (95% CI 1.2-6.3) and 2.5 for other etiologies (95% CI 0.95-6.31) 
compared to autoimmune liver disease (HR=1). 
Identification of risk factors for HCC and derivation of the Toronto HCC 
Risk Index (THRI) 
By univariate Cox regression, age, sex, etiology, APRI, FIB-4, MELD and platelet 
count were significantly associated with the development of HCC (Table 2). 
Schoenfeld’s residuals confirmed the validity of the assumptions used in the Cox 
methodology. 
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Variables were combined in a backward stepwise multivariable Cox model 
avoiding collinear variables like FIB-4 and APRI. The final multivariable model 
with the lowest AIC included age, male sex, etiology of cirrhosis (HBV, HCV, 
HCV with SVR, Steatohepatitis, Autoimmune and Other), and platelet count  
(Table 2).   No significant interactions were detected between variables. 
Treatment for HBV was not an independent predictor of HCC in this cohort, since 
the majority (76%) of patients were on treatment.  
The Toronto HCC risk index (THRI) was then derived using HRs of the variables 
in the multivariable model (Table 3). Point scores were assigned to each 
covariate in proportion to the HR for that variable, using a common denominator 
to compare the HR of significant covariates and then rounding scores to the 
nearest integer, following the method of Yang and colleagues [28].  
Patients were then stratified into three equally-spaced groups based on the THRI 
score (<120, 120-240, and >240 points). These cutoffs were chosen in order to 
create maximum separation between the risk groups. Patients with a low THRI 
score (<120) had a 5-year cumulative HCC incidence of 1.2% (95% CI 0.13-
2.2%) and a 10-year cumulative incidence of 2.7% (95% CI 0.3-5.1%).  Patients 
in the intermediate-risk group (120-240 points) had a cumulative incidence of 
4.4% (95% CI 3.1-5.6%) at 5 years and 9.8% (95% CI 7.3-12.3%) at 10 years. 
The high-risk group (THRI >240) had a higher 5- and 10-year cumulative 
incidence of HCC of 15.4% (95% CI 12.7-17.9%) and 32.1% (95% CI 27.4-
36.4%), respectively. The cumulative HCC incidence by THRI score is shown in 
figure 2. The modified Harrell’s c-statistic for the multivariable model was 0.76 
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(95% CI: 0.72-0.79) with platelets as a continuous variable, and 0.75 with 
platelets as a categorical variable. This analysis was repeated after excluding 
patients with F3 (advanced fibrosis) and no other clinical, radiologic or laboratory 
manifestations of cirrhosis. The c-statistic for this subset was 0.74.  
The 5- and 10-year HCC incidence was obtained for each THRI point score. 
These data were used to develop a nomogram for HCC incidence by point score 
to allow for more individualized risk assessment (Figure 3).  
External Validation 
External validation of the model was performed in a cohort of 1,144 cirrhotic 
patients from Rotterdam, Netherlands (PBC n=408, HBV n=253, HCV n=301, 
HCV-SVR n=182). A total of 107 patients (9.4%) among the validation cohort 
developed HCC during follow-up. Cumulative HCC incidence in the low, 
moderate and high risk groups at 5 years was 1.1% (95%CI 0.0- 2.3%), 4.9% 
(95%CI 2.4- 7.5%), 13.1% (95%CI 9.6- 16.6%) and at 10 years 3.6% (95%CI 
1.1-6.2%), 8.9% (95%CI 4.6- 13.2%), 24.3% (95%CI 18.4- 30.1%) respectively 
(Figure 4).  The predicted mean HCC incidence coincides with the observed 
Kaplan-Meier HCC-incidence of the 3 risk groups (Figure 4) reflecting a good 
calibration (the overall calibration slope is 0.95 (SE 0.05), not significantly 
different from 1) and with similar predictive ability (Harrell’s c-statistic 0.77) in the 
validation cohort as seen in the derivation cohort. The calibration slope of the 
prognostic risk score in the validation dataset was 0.93 (SE 0.10), which is not 
significantly different from 1 (p=0.48), and thus the calibration seems to be 
preserved. 
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Discussion 
HCC is one of the most common causes of morbidity and mortality for patients 
with chronic liver disease. HCC screening protocols consume significant time and 
resources and currently do not stratify patients based on their individualized risk 
of HCC.  Our large clinic-based cohort of cirrhotic patients (n=2,079), with long-
term follow-up (median 71 months), encompassing a comprehensive range of 
liver disease, provides important data on HCC incidence with development of a 
simple scoring system to stratify patients based on their risk of HCC over time. 
Current guidelines for HCC surveillance advise biannual surveillance for all 
patients with cirrhosis using ultrasound[6].  This recommendation applies to all 
patients regardless of the etiology of cirrhosis and other risk factors.  The 6-
month interval was selected based on tumor doubling time and in part from cost-
effectiveness analyses showing that an annualized HCC incidence of 1.5% or 
more would make surveillance cost-effective[11]. However, the disease-specific 
risk for HCC has not been clearly established for all etiologies of cirrhosis. Our 
data clearly show that the etiology of cirrhosis is a critical determinant of HCC 
risk that can be summarized with etiologic categories.  
Patients with chronic viral hepatitis had the highest cumulative risk of HCC, 
whereas those with autoimmune liver diseases had the lowest risk. For many 
etiologies of cirrhosis, the annualized incidence of HCC was lower than the 
AASLD recommended threshold for biannual screening to be cost-effective 
(1.5% per year). In our cohort, these included AIH (0.17% per year), PBC (0.6% 
per year), PSC (0.7% per year) and possibly NAFLD (1.3% per year). Notably 
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patients with CHC who were successfully treated and achieved a sustained 
virological response (SVR) had an HCC incidence similar to that in patients with 
autoimmune liver disease. 
There is some variability in the published estimates of HCC incidence by etiology 
of cirrhosis, partially because many studies report incidence over the study 
period rather than annualized risk.  The observed annualized incidence of HCC 
in this study was similar to estimates reported previously for each specific 
etiology of cirrhosis[14,29-31]. 
To aid in risk stratification for individual patients, an easy-to-use scoring system, 
using a combination of routine clinical and laboratory parameters (age, sex, 
etiology and platelets), was developed to predict the risk of HCC in patients with 
cirrhosis. The THRI was able to stratify patients into low, intermediate and high 
risk of HCC. Patients in the low-risk group had an annual HCC incidence of 
approximately 0.3% - well below the threshold for cost-effective surveillance – 
whereas the incidence in the high-risk group was 3.2% per year, suggesting that 
these patients require close follow-up. 
To assess whether patients with cryptogenic cirrhosis should have been 
classified with the ‘Other’ group vs the ‘Fatty liver’ group, we evaluated the risk of 
HCC in the ‘Other’ group versus the ‘Cryptogenic’ group using the log-rank test 
and found that there was no significant difference.  Of the 35 patients with 
cryptogenic cirrhosis in this cohort, only 2 developed HCC, which is lower than 
would be expected if they all had NAFLD. Therefore, although it may be that 
some of these patients had NAFLD, none had associated clinical conditions and 
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thus it seems more appropriate to classify those with ‘Cryptogenic’ cirrhosis in 
the ‘Other’ category 
The strengths of this study include the large patient cohort, the long-term follow-
up and the large number of patients with autoimmune liver disease included. 
Importantly external validation confirmed the good predictive ability of the scoring 
system in an independent cohort of cirrhotic patients of varying etiology. While 
previous studies have developed etiology-specific HCC-risk scores[20,28], the 
THRI allows for HCC risk stratification for all cirrhotic patients, regardless of 
etiology. Importantly, as patients age, and disease progresses, the THRI score 
will also increase. Alternatively, if a patient with CHC is treated and achieves 
SVR, the THRI and corresponding risk of HCC will go down. 
This study has limitations, largely relating to its retrospective design.  The scoring 
system was developed in a single large tertiary care liver clinic, however it was 
validated in an independent population with similar predictive ability. Given the 
retrospective nature of the THRI score development further prospective studies 
including data on other risk factors and causes of morbidity and mortality are 
required to confirm the predictive ability of the THRI score.  Notably, 119 patients 
were followed for between 6-12 months meaning that they only underwent one 
surveillance ultrasound during follow-up. These patients were included in the final 
analysis to maximize the power of the scoring system, noting that their short 
follow-up time is accounted for using survival analysis. The diagnosis of NAFLD 
and alcoholic liver disease was recorded based on the clinical opinion of the 
hepatologist that assessed the patient rather than by using standardized alcohol 
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assessment tools, which may have led to some degree of misclassification. 
However, in the final risk score, both NAFLD and alcoholic liver disease are 
categorized in one subgroup (Steatohepatitis), since the HCC risk among these 
groups is similar. Data on the race/ethnic background of patients was not 
available in the databases used nor was data on competing risks for mortality 
and as such the risk of HCC was not adjusted for competing risks, which may be 
relevant given that all patients had cirrhosis.  
Data on adherence to 6-monthly ultrasound were not available for all patients. 
Among patients surveyed at UHN, the adherence to screening guidelines was 
poor (35%), but in line with prior estimates[32]. However, given the rapidly 
progressive nature of untreated HCC, it is very unlikely that this affected the 
incidence estimates significantly, and likely did not affect the comparison 
between etiologic categories. Lastly, data on competing risks of mortality from 
other causes was not available to us. This may potentially impact the estimates 
of HCC incidence obtained in this study. However, given that patients were 
cirrhotic at entry, we do not expect this to have a marked differential impact on 
estimates between etiologic categories.  
In conclusion, in a large cohort of cirrhotic patients with a representative 
spectrum of underlying liver disease, HCC risk varied widely according to the 
etiology of cirrhosis. Routine clinical and laboratory data were used to develop an 
easy-to-use scoring system to predict HCC risk over time, which was validated in 
an independent cohort of patients with cirrhosis.  This tool may be used to 
identify patients at very low risk of HCC, who may not require surveillance.   
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Table 1: Baseline characteristics of patients with cirrhosis (follow-up 
>6months) and patients with HCC 
 Derivation cohort Validation cohort 
  
All patients 
(n=2,079) HCC (n=226) 
All patients 
(n=1,144) 
HCC 
(n=107) 
Mean Age (yrs) 
±SD 53.9±12.4  57.3±11.0 51.2±11.6  54.2±10.0 
 (Range) (15-93) (20-83) (14-81) (26-76) 
 
    
Sex 
  
  
Female n (%) 828 (39.9) 44 (19.5) 569 (49.7) 30 (28.0) 
Male n (%) 1251 (60.1) 182 (80.5) 575 (50.3) 77 (72.0) 
 
    
Mean follow-up 
(yrs)±SD  5.9±3.5  3.9±2.6  7.3±5.1  5.4±4.4  
Median  
(Range) 
5.4 
(0.5-18.6) 
3.4 
(0.5-15.3) 
6.2 
(0.5-26.7) 
4.2 
(0.5-22.0) 
 
    
Etiology, n (%) 
  
  
HBV 396 (19.0) 69 (30.5) 253 (22.1) 23 (21.5) 
HCV-No SVR 692 (33.3) 102 (45.1) 301 (26.3) 60 (56.1) 
HCV-SVR 
ALD 
191 (9.2) 
228 (11.0) 
9 (3.9) 
20 (8.8) 182 (15.9) 7 (6.5) 
NAFLD 111 (5.3) 8 (3.5) 
  
AIH 112 (5.4) 1 (0.4) 
  
PBC 108 (5.2) 4 (1.8) 408 (35.7) 17 (15.9) 
PSC 40 (1.9) 2 (0.9) 
  
Other 201 (9.7) 11 (4.9) 
  
 
    
Mean BMI 
(kg/m2)±SD 26.4±5.2 26.1±4.6 Not available Not available 
(Range) (14.9-52.5) (18.3-40.7)   
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 Table 2: Factors associated with HCC by Cox proportional hazards 
regression  
Covariate Univariable HR p-value 
Multivariable 
HR p-value 
(95% CI) (95% CI) 
Etiology 
Autoimmune 1 1 
HCV-SVR 1.74 (0.65-4.67) 0.27 1.04 (0.38-2.83) 0.94 
Other 2.46 (0.95-6.34) 0.06 1.65 (0.63-4.27) 0.31 
Steatohepatitis 4.14 (1.80-9.51) 0.001 2.12 (0.91-4.92) 0.08 
HCV 6.74 (3.13-14.50) <0.001 3.83 (1.76-8.33) 0.001 
HBV 6.50 (2.99-14.16) <0001 3.66 (1.66-8.07) 0.001 
 Age 1.03 (1.02-1.05) <0.001 1.04 (1.03-106) <0.001 
 Age category 
<45 1 1 
45-60 1.91 (1.27-2.87) 0.002 1.94 (1.28-2.93) 0.002 
>60 2.94 (1.94-4.46) <0.001 3.77 (2.45-5.80) <0.001 
 Male Sex 2.84 (2.04-3.94) <0.001 2.92 (2.07-4.12) <0.001 
 Platelets (x109/L) 0.99 (0.99-0.99) <0.001 0.99 (0.99-1.00) <0.001 
 Platelet Category 
(x109/L) 
<80 1 1 
80-139 0.78 (0.57-1.07) 0.12 0.78 (0.57-1.07) 0.13 
140-200 0.40 (0.27-0.59) <0.001 0.40 (0.27-0.60) <0.001 
>200 0.25 (0.16-0.41) <0.001 0.31 (0.19-0.50) <0.001 
 APRI NS 
<1.5 1 
1.5-4 1.69 (1.26-2.28) <0.001 
>4 1.57 (1.09-2.26) 0.01 
 FIB-4 NS 
0-1.5 1 
1.5-5.5 2.55 (1.44-4.53) 0.001 
>5.5 4.10 (2.29-7.34) <0.001 
 MELD>8 1.61 (1.23-2.11) 0.001 NS 
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Table 3: Components of the Toronto HCC Risk Index 
Risk Factor Score 
Age 
<45 
45-60 
>60 
 
0 
50 
100 
Etiology 
Autoimmune 
HCV SVR 
Other 
Steatohepatitis 
HCV 
HBV 
 
0 
0 
36 
54 
97 
97 
Gender 
Female 
Male 
 
0 
80 
Platelets 
>200 
140-200 
80-139 
   <80 
 
0 
20 
70 
89 
 
Total 
 
0-366 
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Table 4: Crude HCC incidence according to etiology  
 N at 
baseline 
5-year 
cumulative 
incidence 
(95% CI) 
10-year 
cumulative 
incidence 
(95% CI) 
Incidence per 
1000 person-
years 
(95% CI) 
Etiology 
    
HBV 396 13.0%  
(9.9-16.9) 
23.2 %  
(18.5-28.8) 
26.2  
(20.7-33.1) 
HCV 883 9.0%  
(7.1-11.4) 
21.1%  
(17.5-25.3) 
21.9  
(18.2-26.4) 
ALD 228 9.9%  
(5.9-16.1) 
17.7%  
(10.6-28.9) 
18.4  
(11.9-28.5) 
NAFLD 111 7.7%  
(3.5-16.6) 
12.8%  
(6.3-25.1) 
14.4  
(7.2-28.8) 
AIH 112 0% 1.7%  
(0.2-11.4) 
1.3  
(0.2-9.4) 
PBC 108 3.4%  
(1.1-10.3) 
6.1%  
(2.1-16.9) 
5.5  
(2.0-14.6) 
PSC 40 2.5%  
(0.4-16.6) 
6.9%  
(1.7-25.9) 
7.2  
(1.8-28.9) 
Other 201 4.5%  
(2.1-9.2) 
8.0%  
(4.2-14.9) 
10.1  
(5.6-18.3) 
Etiologic 
category 
    
Viral 1279 10.3%  
(8.6-12.3) 
21.7%  
(18.8-25.0) 
23.3  
(20.2-27.0) 
Steatohepatitis 339 9.1%  
(5.9-13.8) 
16.3%  
(10.6-24.5) 
17.0  
(11.8-24.7) 
Autoimmune 260 1.8%  
(0.7-4.7) 
4.6%  
(2.0-10.1) 
4.0  
(1.9-8.3) 
Other 201 4.5%  
(2.1-9.2) 
8.0%  
(4.214.9) 
10.1  
(5.6-18.3) 
 
 
 
 
 
 
 
 
 
  
25 
 
Supplementary Table 1: Baseline characteristics of patients with cirrhosis 
and follow-up >6 months 
Etiology of 
cirrhosis 
N 
(total 
2079) 
 
Mean Age 
±SD 
[years] 
Sex 
 (% 
male) 
Mean 
follow-up, 
±SD 
[years] 
Mean BMI 
±SD 
[Kg/m2] 
HBV 396 52.4±12.6 74% 6.7±3.6 24.9±4.5 
HCV 883 53.9±10.8 63% 5.7±3.4 26.9±5.1 
ALD 228 55.3±11.2 77% 4.7±3.5 27.7±5.8 
NAFLD 111 60.5±10.6 51% 5.0±3.2 30.0±6.0 
AIH 112 50.7±17.1 27% 6.7±3.3 26.9±5.1 
PBC 108 57.3±12.4 12% 6.8±3.8 24.6±4.2 
PSC 40 46.4±17.2 62% 6.9±3.5 25.2±4.4 
Other 201 53.5±14.6 57% 5.6±3.6 25.3±5.5 
Viral 1279 53.4±11.4 66% 6.0±3.5 26.2±5.0 
Steatohepatitis 339 57.0±11.2 65% 4.8±3.4 28.6±5.9 
Autoimmune 260 52.8±15.8 26% 6.8±3.5 25.8±4.8 
 
 
 
 
Supplementary Table 2: C-statistic and 95% CI by subgroup in development 
and validation cohorts 
Etiology C stat Lower limit Upper limit 
Derivation Cohort 
Autoimmune 0.73 0.71 0.78 
Steatohepatitis 0.79 0.76 0.80 
HBV 0.72 0.69 0.78 
HCV 0.71 0.68 0.79 
Validation Cohort 
PBC 0.68 0.56 0.80 
HBV 0.77 0.67 0.87 
HCV 0.71 0.64 0.77 
HCV-SVR 0.73 0.63 0.83 
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Figure Legends 
 
Figure 1: Cumulative incidence of HCC by etiology and disease category:  
The cumulative incidence of HCC is shown for (a) patients with viral hepatitis 
(chronic HBV and chronic HCV), (b) patients with steatohepatitis (alcohol or 
NASH) and (c) patients with autoimmune liver disease (AIH, PBC and PSC).  
The cumulative incidence of HCC is also compared across etiologic categories 
(d). Cumulative incidence is compared between groups using the log-rank test.  
 
 
Figure 2: Cumulative HCC incidence by Toronto HCC Risk index (THRI) 
The THRI stratified patients into low, intermediate and high risk. Patients with a 
THRI score below 120 had an annualized HCC incidence of 0.3% per year. The 
annualized incidence in patients with intermediate risk (120-240 points) was 
1.0% whereas for patients with high risk (>240 points) was 3.2%.  The curves for 
the 3 risk groups were compared using the log-rank test. 
  
Figure 3: Nomogram for 5- and 10-year HCC incidence based on THRI 
point-score.  The 5 and 10-year HCC incidence was calculated for each point 
score allowing for individualized risk assessment. The cumulative HCC incidence 
for a given THRI score equals 1 – S0(t)exp(β*THRI) , where S0 is the estimated 
baseline HCC-free survival at time t and β=0.013227, the estimated effect of 
each additional THRI point.
 
  
 
Figure 4: Observed vs. Predicted HCC incidence in the validation cohort: 
Observed and expected cumulative Incidence of HCC in the validation dataset for the 
three risk groups: >240 (red), 120-240 (green) and <120 (blue). Jagged lines (with dots) 
observed HCC incidence obtained by Kalpan-Meier method. Dark colored lines: 
predicted HCC incidence obtained from the THRI and baseline survival function 
estimated from the derivation dataset.   
 
 
Supplementary Figure 1: Patient flow: 12,199 patients were seen in the clinic 
during the study period. Using APRI and FIB-4 cutoffs, 3,064 patients had 
probable cirrhosis.  Charts of all of these patients were reviewed and 2,416 
(79.5%) had clinical, radiological or histological evidence of cirrhosis.  Of these, 
2,079 patients were followed for >6 month and constituted the at risk cohort, of 
whom 226 developed HCC during follow-up.  
Supplementary Figure 2: Calibration plot contrasting predicted vs. observed 10-
year risk (probability) of HCC in the internal validation cohort 
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Highlights 
 
• HCC incidence varies markedly by etiology of cirrhosis.  
• THRI is simple to use, has good predictive ability, and has been externally 
validated  
• THRI may help to refine  HCC surveillance guidelines for cirrhotic patients 
 
  
Figures 
 
 
Figure 1: Cumulative incidence of HCC by etiology and disease category:  
The cumulative incidence of HCC is shown for (a) patients with viral hepatitis 
(chronic HBV and chronic HCV), (b) patients with steatohepatitis (alcohol or 
NASH) and (c) patients with autoimmune liver disease (AIH, PBC and PSC).  
The cumulative incidence of HCC is also compared across etiologic categories 
(d). Cumulative incidence is compared between groups using the log-rank test.  
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Figure 2: Cumulative HCC incidence by Toronto HCC Risk index (THRI) 
The THRI stratified patients into low, intermediate and high risk. Patients with a 
THRI score below 120 had an annualized HCC incidence of 0.3% per year. The 
annualized incidence in patients with intermediate risk (120-240 points) was 
1.0% whereas for patients with high risk (>240 points) was 3.2%.  The curves for 
the 3 risk groups were compared using the log-rank test. 
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Figure 3: Nomogram for 5- and 10-year HCC incidence based on THRI 
point-score.  The 5 and 10-year HCC incidence was calculated for each point 
score allowing for individualized risk assessment. The cumulative HCC incidence 
for a given THRI score equals 1 – S0(t)exp(β*THRI) , where S0 is the estimated 
baseline HCC-free survival at time t and β=0.013227, the estimated effect of 
each additional THRI point.
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Figure 4: Observed vs. Predicted HCC incidence in the validation cohort: 
Observed and expected cumulative Incidence of HCC in the validation dataset for the 
three risk groups: >240 (red), 120-240 (green) and <120 (blue). Jagged lines (with dots) 
observed HCC incidence obtained by Kalpan-Meier method. Dark colored lines: 
predicted HCC incidence obtained from the THRI and baseline survival function 
estimated from the derivation dataset.   
 
  
 
 
Supplementary Figure 1: Patient flow: 12,199 patients were seen in the clinic 
during the study period. Using APRI and FIB-4 cutoffs, 3,064 patients had 
probable cirrhosis.  Charts of all of these patients were reviewed and 2,416 
(79.5%) had clinical, radiological or histological evidence of cirrhosis.  Of these, 
2,079 patients were followed for >6 month and constituted the at risk cohort, of 
whom 226 developed HCC during follow-up.  
  
 
 
Supplementary Figure 2: Calibration plot contrasting predicted vs. observed 10 
year risk (probability) of HCC in the internal validation cohort 
 
 
